Skip to main content

Advertisement

Figure 1 | Arthritis Research & Therapy

Figure 1

From: The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age

Figure 1

C-reactive (CRP) in mg/dl, serum amyloid A (SAA) in mg/l and global physician assessment during 12 months of follow-up in patients with Muckle-Wells Syndrome (MWS) and overlapping MWS/chronic infantile neurological cutaneous and articular syndrome (CINCA). Panel A: patients with MWS and overlapping MWS/CINCA; panel B: patients with CINCA. Arrows represent changes in the treatment schedule (dose or frequency). Pt, patient.

Back to article page